Role of angiotensin receptor-neprilysin inhibitor in diabetic complications

doi:10.4239/wjd.v15.i5.867

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1984)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series.

Item

Count

PDF

WORD

HTML

1095

Figures (1-2)

165

Sum=1299

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

107

Download

241

Sum=348

Publishing Process of This Article

Item

Count

Browse

Download

200

Sum=233

May 15, 2024 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. May 15, 2024; 15(5): 867-875
Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.867

Full Size Figure Download Figure

Figure 1 Mechanisms of angiotensin receptor-neprilysin inhibitor in diabetes. Angiotensin receptor-neprilysin inhibitor, a 1:1 combination of valsartan and sacubitril, reduces the damage due to diabetes mainly by reducing the degradation of natriuretic peptides and inhibiting the effect of Ang II and endothelin-1. ARNI: Angiotensin receptor-neprilysin inhibitor; NEPi: Neprilysin inhibitor; ARB: Angiotensin receptor blocker; BNP: Brain natriuretic peptide; ANP: Atrial natriuretic peptide; CNP: C-type natriuretic peptide; DPP-4: Dipeptidyl peptidase-4; GLP-1: Glucagon-like peptide 1.

Citation: Liu Y, Lu CY, Zheng Y, Zhang YM, Qian LL, Li KL, Tse G, Wang RX, Liu T. Role of angiotensin receptor-neprilysin inhibitor in diabetic complications. World J Diabetes 2024; 15(5): 867-875
URL: https://www.wjgnet.com/1948-9358/full/v15/i5/867.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i5.867